9 results about "Pneumovirus" patented technology

Disclosed herein are nanostructures and uses thereof, comprising a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides selected from I53_dn5A, I53_dn5A.1, and I53_dn5A.2, or variants thereof, and a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides that are I53_dn5B or a variant thereof, wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form the nanostructure; and the nanostructure displays multiple copies of F protein or antigenic fragment thereof of one or more paramyxoviruses and / or pneumoviruses, respectively.

Disclosed herein are nanostructures and their use, where the nanostructures include(a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides;(b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide;wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; andwherein the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

The invention relates to the novel use of an immunogenic formulation containing the bacillus Calmette-Guérin (BCG) strain at a concentration between 10-10° bacteria, expressing at least one protein or immunogenic fragment of respiratory syncytial virus (RSV, Human Orthopneumovirus), in a pharmaceutically acceptable saline buffer solution because it serves to prepare a vaccine useful to prevent, treat, or attenuate human Metapneumovirus (hMPV) infections.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

The invention relates to the field of virus genetic manipulation, in particular to a mouse pneumovirus reverse genetic manipulation system and application thereof. The system comprises: (1) a transcription plasmid, wherein the transcription plasmid can transcribe a genome full-length cDNA sequence of the mouse pneumovirus; (2) a plurality of helper plasmids, wherein the helper plasmids can respectively express N protein, P protein, M2-1 protein and L protein of the mouse pneumovirus; (3) a plasmid for expressing T7 polymerase; wherein the transcription plasmid also transcripts a gene for coding a foreign protein at the same time, and the gene for coding the foreign protein is located between the gene for coding the SH protein and the gene for coding the G protein of the mouse pneumovirus. According to the invention, the problems of low efficiency and complex operation of the mouse pneumovirus reverse genetic system are improved, and the system stability is enhanced.

Chimeric polypeptides, chimeric fusion proteins, immunogenic compositions, and methods of use thereof for pan-pneumovirus vaccination are provided. The chimeric polypeptides typically include immunodominant epitopes of the fusion protein of respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and preferably include one or more of antigenic sites Ø, V, and II of RSV, and III, IV, and DS7 of hMPV. The chimeric polypeptides can be utilized as the antigenic domain in chimeric fusion proteins include one or more additional domains such as a signal peptide sequence, a trimerization domain, a cleavage site, a purification tag or report sequence, and one or more linker sequences. Nucleic acids encoding the chimeric polypeptides and chimeric fusion proteins are also provided, as are recombinant viruses having the same. Pharmaceutical compositions including one or more of the foregoing compositions, and methods of there use for immunizing subjects against RSV and hMPV are also provided.

Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

Disclosed herein are nanostructures and their use, where the nanostructures include(a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides;(b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide;wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; andwherein the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

To provide subunit vaccines with nanostructure-based vaccines.SOLUTION: Provided herein are nanostructures and their use, where the nanostructures include: a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides selected from I53_dn5A, I53_dn5A.1 and I53_dn5A.2, or variants thereof; and a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides being I53_dn5B or a variant thereof; where the first assemblies non-covalently interact with the second assemblies to form a nanostructure; and where the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof.SELECTED DRAWING: None